Vaccination to prevent human papillomavirus infections: From promise to practice

1. WHO. Human papillomavirus vaccines: WHO position paper, October 2014. WER No. 43, 2014, 89, 465–492. Available from: 2014 http://www.who.int/wer/2014/wer8943.pdf?ua=.

2. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence, Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

3. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infectious Diseases, 2013;13:39. doi: 10.1186/1471-2334-13-39 23347441

4. Banura C, Mirembe F, Orem J, Mbonye A, Kasasa S, Mbidde E. Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: a systematic review and meta-analysis. Infect Agent Cancer. 2013;8:27. doi: 10.1186/1750-9378-8-27 23842471

5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of papillomavirus and related diseases. Vaccine. 2012 Nov 20;30 Suppl 5:F12–23. doi: 10.1016/j.vaccine.2012.07.055 23199955

6. Drolet M., Benard, E., Brisson, M. Population-level impact and herd effects following papillomavirus immunization programmes: a systematic review and meta-analysis. Presented at meeting of the Strategic Advisory Group of Experts on immunization, October 2016. Available from: http://www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/.

7. Ali H, Donovan B, Wand H, Read T, Regan D, Grulich A, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032 23599298

8. WHO. Weekly epidemiological record No. 48, 2016, 91, 561–84. Available from: http://apps.who.int/iris/bitstream/10665/251810/1/WER9148.pdf?ua=1.

9. Brotherton J, Zuber P, Bloem P. Primary prevention of HPV through vaccination: update on the current global status. Curr Obst Gynecol Reports. 2016;5:210–24.

10. WHO/IVB Database, data presented to the Strategic Advisory Group of Experts on Immunization (SAGE) in October 2016, Available from: http://www.who.int/immunization/sage/meetings/2016/october/Session10-Update-on-HPV-vaccine-introduction-and-programmatic-perspectives.pdf?ua=1.

11. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch F, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul;4(7):e453–63. doi: 10.1016/S2214-109X(16)30099-7 27340003

12. WHO. Decade of Vaccines, Global Vaccine Action Plan. Available from: http://www.who.int/immunization/global_vaccine_action_plan/DoV_GVAP_2012_2020/en/.

13. Gavi, the Vaccine Alliance. Human papillomavirus vaccine support: Gavi's response and partners. Available from: http://www.gavi.org/support/nvs/human-papillomavirus/.

14. WHO. Global Action Plan for the Prevention and Control of NCDs 2013–2020. Available from: http://www.who.int/nmh/events/ncd_action_plan/en/.

15. WHO. Global Health Sector Strategies for HIV, viral hepatitis, STIs, 2016–2021. Available from: http://www.who.int/hiv/strategy2016-2021/en/.

16. The Global Advisory Committee on Vaccine Safety (GACVS). Safety of human papillomavirus vaccines. Available from: http://www.who.int/vaccine_safety/committee/reports/wer9103.pdf?ua=1.

17. PAHO revolving fund. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=1864%3A2014-paho-revolving-fund&catid=839%3Arevolving-fund&Itemid=4135&lang=fr.

18. WHO V3P Database. Available from: http://www.who.int/immunization/programmes_systems/procurement/v3p/platform/module1/en/.

19. Clendinen C, Zhang Y, Warburton R, Light D. Manufacturing costs of HPV vaccines for developing countries. Vaccine 2016 Nov 21;34(48):5984–89. doi: 10.1016/j.vaccine.2016.09.042 27771183

20. Dorji T, Tshomo U, Phuntsho S, Tamang T, Tshokey T, Baussano I, et al. Introduction of a national HPV vaccination program into Bhutan. Vaccine 2015;33(31):3726–30 doi: 10.1016/j.vaccine.2015.05.078 26057136

21. WHO. Scaling up HPV vaccine introduction. World Health Organization, Geneva; 2016 Available from: http://www.who.int/immunization/diseases/hpv/scaling-up-intro/en/.

22. Hanley SJ, Yoshioka E, Ito Y, Kishi E. HPV vaccination crisis in Japan. Lancet. 2015;385:2571. doi: 10.1016/S0140-6736(15)61152-7 26122153

23. WHO. Options for linking HPV vaccines with other health interventions for adolescents. World Health Organization, Geneva; 2013. Available from: http://www.who.int/immunization/diseases/hpv/scaling-up-intro/en/.

24. Kreimer A, Struyf F, Del Rosario-Raymundo M, Hildesheim A, Skinner S, Wacholder S, et al. Efficacy of fewer than three doses of an HPV- 16/18 AS04 adjuvanted vaccine: combined analysis of data from the Cosa Rica vaccine trial and the PATRICIA Trial. Lancet Oncol. 2015;16(7):775–86. doi: 10.1016/S1470-2045(15)00047-9 26071347

25. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al.; Indian HPV Vaccine Study Group. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2016 Jan;17(1):67–77. doi: 10.1016/S1470-2045(15)00414-3 26652797

26. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016 Feb;13[2]:119–32. doi: 10.1038/nrclinonc.2015.146 26323382